How much revenue does Ajanta Pharma make?

Ajanta Pharma reported 46.48 billion INR in revenue for fiscal year 2025, up 10.4% from 42.09 billion INR in fiscal year 2024. In Q1 2026 revenue was 13.03 billion INR.

Where does Ajanta Pharma make most of its revenue?

Emerging Market: 42% of revenue by region in fiscal year 2025, followed by India (32%).

What companies are similar to Ajanta Pharma?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Abbott India Limited (ABBOTINDIA.NS), Ipca Laboratories Limited (IPCALAB.NS), GlaxoSmithKline Pharmaceuticals Limited (GLAXO.NS), J. B. Chemicals & Pharmaceuticals Limited (JBCHEPHARM.NS).

Ajanta Pharma Limited (AJANTPHARM.NS) Stock

About Ajanta Pharma Limited

Ajanta Pharma Limited, together with its subsidiaries, a pharmaceutical formulation company engages in the development, manufacture, and marketing of specialty pharmaceutical finished dosages. The company offers chronic and acute therapies; branded generic products; and a range of dosage forms, including tablets, capsules, eye drops, dry powder suspension, injectables, inhalers, ointments, creams,...

At a glance

Ajanta Pharma reported revenue of 46.48 billion INR for fiscal year 2025, up 10.4% from fiscal year 2024, and net income of 9.20 billion INR. In Q1 2026 (the quarter ended June 30, 2025) revenue was 13.03 billion INR, up 13.8% from a year before. Emerging Market was its largest region in fiscal year 2025, with 42% of revenue.

Figures from company filings; latest fiscal year ended March 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.